I collect drinking straws. Not just any old straws, mind you, but long, wide-barreled plastic straws. My assortment includes several unusual straws as well, and they all help me drink beverages with ease even though I have dysphagia, or difficulty swallowing — a symptom of ALS. As I wrote…
Biotech company Auttx has received a $125,000 grant to advance the development of new molecules that aim to restore normal RNA processing in people with amyotrophic lateral sclerosis (ALS), potentially leading to new treatments for ALS. Messenger RNAs are intermediate molecules that are produced when genes are read to…
Alterations in the activity of ancient viral DNA that have been incorporated into the human genome may contribute to the development of amyotrophic lateral sclerosis (ALS), according to a study led by researchers at King’s College London. While earlier studies had started to identify connections between these ancient viruses…
When ALS impacted Rocío's husband Francisco, she knew the disease couldn't shake their greatest source of love and support—their family. Hear how they worked together to get Francisco the understanding and treatment he needed.
Avicenna Biosciences has received its first patent covering new ROCK inhibitor compounds that may be used to treat amyotrophic lateral sclerosis (ALS) and similar disorders. The U.S. patent grants Avicenna exclusive rights to pharmaceutical products containing inhibitors of the Rho associated protein kinases 1 and 2 (ROCK1/2). It also…
NurOwn (debamestrocel) is an investigational cell-based therapy designed to slow disease progression and potentially extend survival in people with ALS. It is being developed by BrainStorm Cell Therapeutics to be given as regular intrathecal injections, or into the spinal canal.
Handling night care has been one of the hardest parts about managing ALS for my husband, Todd, but now I’m hopeful because he’s been training himself to sleep on his back. Todd has been a side sleeper, and for years he had to be turned from side to side…
Long-term treatment with the cell therapy NurOwn (debamestrocel) was found to significantly extend survival in people with amyotrophic lateral sclerosis (ALS) when compared with a matched control group from previous clinical trials, according to new data. That data, from an expanded access program (EAP), was shared by NurOwn’s…
Neurosense Therapeutics will meet with the U.S. Food and Drug Administration (FDA) Nov. 6 to discuss plans for a Phase 3 trial to test its experimental therapy PrimeC in amyotrophic lateral sclerosis (ALS). The company said it will give an update on results of the Type C meeting following…
Hmmmmm. That’s what my body feels when it’s doing its “humming thing.” It’s an all-over buzzy sensation that I chalk up to being another quirky symptom of my ALS. It’s a feeling I’ve never mentioned during my ALS clinic visits, mainly because I want to keep the visit rolling along…
